Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Enantiomers, Antibiotics May Benefit As Hatch Pushes Incentives In FDA Bill

Executive Summary

Exclusivity and other incentives to encourage antibiotic development are among the details being negotiated by Senate Health, Education, Labor and Pensions Committee members as part of the FDA Revitalization Act

You may also be interested in...



Forest’s Fetzima Will Test Enantiomer Exclusivity Policy Change

The antidepressant levomilnacipran, an enantiomer of Forest’s fibromyalgia drug Savella (milnacipran), could be the first product to take advantage of an FDA Amendments Act provision that allows enantiomers of previously approved drugs to qualify for five years of new chemical entity exclusivity.

2007 NME Prospects Plentiful For Wyeth, Novartis – Other Firms Fall Short

The year 2007 holds the potential to fatten Wyeth's new drug lineup: after a lean 2006, when no Wyeth new molecular entities were approved, the company leads the industry in potential NME approvals for the coming year

FDA ENANTIOMER MARKETING EXCLUSIVITY POLICY MAY BE REVISED, AGENCY ANNOUNCES; WYETH/INTERNEURON REDUX EXCLUSIVITY DETERMINATION TO BE MADE BY PTO, FDA SAYS

FDA is soliciting comments on the appropriate exclusivity period for single-isomer versions of previously marketed racemic products, the agency announced in a Jan. 15 Federal Register notice.
UsernamePublicRestriction

Register

PS048302

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel